The Chemours Company stock steadies as PFAS litigation and Q2 loss weigh on outlook
Published on 09/17/2026 at 18:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The Chemours Company stock (ISIN US1638511089) traded around USD 14.70 on the New York Stock Exchange on September 17, 2026, after a prior close of USD 14.42 on September 16, 2026, leaving the chemicals group navigating a recent quarterly loss and persistent PFAS-related litigation risk for investors.
Q2 2026 results show revenue growth but a sharp loss
According to the quarterly data overview for The Chemours Company on September 17, 2026, Q2 fiscal 2026 revenue stood at USD 1.59 billion for the period ended June 30, 2026, compared with year-ago sales of USD 1.50 billion, an increase of about 2.7 percent that underscores modest top-line growth in its performance chemicals portfolio.Yahoo Finance
The same Q2 fiscal 2026 snapshot shows an earnings figure of negative USD 274 million for Chemours, translating into a profit margin of negative 17.22 percent for the quarter ended June 30, 2026, a sharp deterioration compared with a positive margin in the prior-year period and highlighting the impact of charges and weaker profitability on the bottom line.Yahoo Finance
On the earnings per share side, the Q2 fiscal 2026 EPS actual for Chemours came in at USD 0.42 versus an EPS estimate of roughly USD 0.4197, leaving the company essentially in line with consensus for the quarter ended June 30, 2026, after much larger positive surprises in earlier quarters.Yahoo Finance
Analyst estimates and PFAS settlement context
The same analyst overview dated September 17, 2026 indicates that for the current quarter ending September 2026, the average revenue estimate for Chemours stands at USD 1.53 billion, compared with year-ago sales of USD 1.50 billion, implying expected sales growth of about 1.96 percent for full-year 2026 as analysts track how PFAS-related costs and demand trends shape the company’s path.Yahoo Finance
A recent analyst-focused piece on September 17, 2026 covering Corteva highlights that Corteva, EIDP, The Chemours Company and DuPont de Nemours agreed to a USD 455 million settlement with the State of North Carolina over PFAS-related claims, with Corteva’s share at about USD 66 million and the agreement requiring Corteva and DuPont to guarantee Chemours’ portion of the settlement, underlining how legacy PFAS liabilities remain a key risk factor around Chemours even as it works to stabilize earnings.Investing.com
Legal overhangs are reinforced by local reporting dated September 17, 2026 that two residents of Wood County filed suit against Chemours alleging PFAS contamination near a landfill site, adding another case to the company’s litigation docket and reminding the market that environmental claims can translate into further expenses or settlements over time.WTAP
Stock price level and investor perspective
Per the latest price snapshot on September 17, 2026, The Chemours Company stock was quoted at around USD 14.70 on the New York Stock Exchange during intraday trading at about 1:50 p.m. Eastern Time, up roughly 0.14 percent from the prior closing price of USD 14.42 on September 16, 2026, as the market weighed the modest move against the backdrop of a recent quarterly loss and ongoing litigation risks.Yahoo Finance
Key data on The Chemours Company stock
- Company: The Chemours Company
- ISIN: US1638511089
- Ticker: CC
- Trading venue: NYSE
- Price (as of September 17, 2026, 13:50): 14.70 USD
- Market capitalization: 2.00 billion USD (as of September 17, 2026)
- Sector / Industry: Chemicals
- Index membership: S&P 400
